Gender differences in drug bioequivalence: Time to rethink practices

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 3, 2013, Pages 260-262

  Koren, G ^a   Nordeng, H ^b   MacLeod, S ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACECAINIDE; ALPRAZOLAM; CIMETIDINE; ERYTHROMYCIN; GLYCERYL TRINITRATE; KETOPROFEN; PHENYLACETIC ACID;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

AREA UNDER CURVE; FEMALE; HUMANS; MALE; SEX CHARACTERISTICS; THERAPEUTIC EQUIVALENCY;

EID: 84874188816     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.233     Document Type: Review

References (9)

1. US Food and Drug Administration. Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products -General Considerations. (March 2003, Revision 1)
2. European Medicines Agency, Guideline on the investigation of bioequivalence.
3. Koren, G. Pharmacokinetics in pregnancy; clinical significance. J. Popul. Ther. Clin. Pharmacol. 18, e523-e527 (2011
4. Chen, M.L., Lee, S.C., Ng, M.J., Schuirmann, D.J., Lesko, L.J. & Williams, R.L. Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin. Pharmacol. Ther. 68, 510-521 (2000
5. Flores Pérez, J. et al. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol. Int. 20, 485-494 (2003
6. A shiru, D.A., Patel, R. & Basit, A.W. Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. Pharm. Res. 25, 2327-2333 (2008
7. Soldin, O.P., Chung, S.H. & Mattison, D.R. Sex differences in drug disposition. J. Biomed. Biotechnol. 2011, 187103 (2011
8. Kando, J.C., Yonkers, K.A. & Cole, J.O. Gender as a risk factor for adverse events to medications. Drugs 50, 1-6 (1995
9. US Government Accountability Office (GAO), 2010. Washington, DC, 20548. Drug safety: Most drugs withdrawn in recent years had greater health risks for women http://www.gao.gov/new.items/d01286r.pdf Accessed 31 May 2012